Johnson & Johnson $JNJ Shares Sold by Park National Corp OH

Park National Corp OH reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 95,472 shares of the company’s stock after selling 5,221 shares during the quarter. Park National Corp OH’s holdings in Johnson & Johnson were worth $17,702,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in Johnson & Johnson by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock valued at $36,209,060,000 after purchasing an additional 3,085,180 shares in the last quarter. Geode Capital Management LLC boosted its position in Johnson & Johnson by 2.1% in the 2nd quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock valued at $9,227,988,000 after buying an additional 1,225,676 shares during the last quarter. Norges Bank purchased a new stake in shares of Johnson & Johnson during the second quarter worth about $4,877,174,000. Northern Trust Corp lifted its stake in shares of Johnson & Johnson by 0.4% in the first quarter. Northern Trust Corp now owns 30,943,820 shares of the company’s stock worth $5,131,723,000 after acquiring an additional 130,645 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Johnson & Johnson by 2.7% in the second quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company’s stock valued at $3,635,832,000 after purchasing an additional 620,039 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several analyst reports. BMO Capital Markets restated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday. HSBC restated a “buy” rating and issued a $240.00 price target on shares of Johnson & Johnson in a research note on Wednesday, December 10th. JPMorgan Chase & Co. increased their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Tuesday, September 16th. Barclays boosted their target price on shares of Johnson & Johnson from $176.00 to $197.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. Finally, Morgan Stanley increased their price target on shares of Johnson & Johnson from $190.00 to $197.00 and gave the stock an “equal weight” rating in a research report on Friday. Four analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $208.35.

Johnson & Johnson Stock Up 1.3%

Shares of NYSE:JNJ opened at $214.41 on Tuesday. The company’s fifty day moving average is $196.61 and its two-hundred day moving average is $177.85. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $215.19. The stock has a market capitalization of $516.58 billion, a price-to-earnings ratio of 20.70, a price-to-earnings-growth ratio of 2.36 and a beta of 0.36.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.